Abstract 112P
Background
Historical data has demonstrated a synergistic anti-tumor response with the combination of immunotherapy, chemotherapy, and anlotinib for extensive-stage small-cell lung cancer (ES-SCLC). However, real-world evidence supporting this combination regimen is lacking. Therefore, we initiated a multicenter real-world study to evaluate the efficacy and safety of serplulimab (an anti-PD-1 mAb) combined with chemotherapy plus anlotinib for ES-SCLC patients.
Methods
Patients initially diagnosed with ES-SCLC who received serplulimab combined with chemotherapy and anlotinib between October 2020 and June 2024 were eligible for this study. The primary endpoint was overall survival (OS). The secondary endpoints were progress-free survival (PFS) and adverse events (AEs). Subgroup analyses were performed based on the different treatment lines.
Results
A total of 40 patients who received serplulimab combined with chemotherapy and anlotinib with a median age of 63 (range: 50-83) years were included in three centers. The main features included males (77.5%), smokers (67.5%), ECOG score of 1 (57.5%), and stage Ⅳ disease (87.5%). There were 28 patients received serplulimab as the first-line, 9 as the second-line, and 3 as the third-line. Anlotinib was administered to 5 patients in first-line, 13 in second-line, and 22 in third-line therapy. The median follow-up duration was 21.5 months (range: 5.2-46.7). The median OS from the initial diagnosis of all patients was 21.8 months (95%CI 15.6-NR). There was no significant difference in median OS between different anlotinib treatment lines (14.2 vs. NR vs. 21.8 months, P=0.737). The median PFS was numerically higher in patients receiving first-line combination therapy than those not treated with first-line anlotinib in combination (9.2 vs. 6.6 months, P=0.354). Any grade AEs occurred in 30 (75.0%) patients, with anemia being the most common (17, 42.5%). Grade ≥3 AEs were reported in 6 (15.0%) patients.
Conclusions
Our study revealed that serplulimab combined with chemotherapy and anlotinib as a front-line treatment regimen might benefit survival and is well-tolerated for ES-SCLC patients.
Legal entity responsible for the study
Jun Wang.
Funding
Clinical Research Capacity Building and Human Research Participants Protection Practice Platform (CCHRPP).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
216P - Spatial transcriptomics reveals tumor-microenvironment heterogeneity of breast cancer
Presenter: Hyun Lee
Session: Poster Display session
Resources:
Abstract
217P - Tumor-derived CCL15 regulates RNA m6A methylation in cancer-associated fibroblasts to promote hepatocellular carcinoma growth
Presenter: Yueguo Li
Session: Poster Display session
Resources:
Abstract
218P - A novel tumor adenosine signature to guide indication selection for adenosine pathway inhibitors
Presenter: Sophie Dekoninck
Session: Poster Display session
Resources:
Abstract
219P - Radiotherapy, in conjunction with a PI3Kd/? inhibitor, enhances effector CD8+ T cell-mediated anti-tumor immune responses and the memory function of T cells within the tumor microenvironment by stimulating innate immunity
Presenter: Ye hyun Kim
Session: Poster Display session
Resources:
Abstract
220P - Correlation research between oral flora diversity and radiation-induced stomatitis after postoperative radiotherapy for oral squamous cell carcinoma
Presenter: Qin Zheng
Session: Poster Display session
Resources:
Abstract
221P - Chemoradiotherapy induced adaptive anti-tumor T cell immunity in patients with non-small cell lung cancer
Presenter: Yaoyao Xie
Session: Poster Display session
Resources:
Abstract
222P - Features of epithelial-to-mesenchymal transition (EMT) and humoral immune response in ulcerated acral melanoma: A transcriptomic and spatial proteomic analysis.
Presenter: Estefania Vazquez
Session: Poster Display session
Resources:
Abstract
223P - Frequency of the number of myeloid-derived suppressor cells in patients with lung cancer according to T stage
Presenter: Jelena Vukovic
Session: Poster Display session
Resources:
Abstract
224P - Immunological Dynamics in Triple-Negative Breast Cancer: Peripheral Immune Responses to Neoadjuvant Therapy
Presenter: Rita Santos
Session: Poster Display session
Resources:
Abstract
225P - Assessment of immune cell populations in the peripheral blood of metastatic prostate cancer
Presenter: Vanessa Patel
Session: Poster Display session
Resources:
Abstract